Table 1.
Clinical and demographic characteristics of MS patients at the time of the STRATIFY JCV DxSelect test.
| Characteristic | Study Population |
|---|---|
| Number of patients, n | 1405 |
| Sex, female/male, n | 990/415 |
| Mean age, years ± SD | 41.7 ± 12.2 |
| Age, median (IQR; range) | 41.0 (19.0; 18–78) |
| Age categories, n (%) | |
| 18–29 years | 248 (17.7) |
| 30–39 years | 396 (28.2) |
| 40–49 years | 381 (27.1) |
| 50–59 years | 267 (19.0) |
| ≥60 years | 113 (8.0) |
| Disease course, n (%) | |
| RRMS | 955 (68.0) |
| SPMS | 268 (19.0) |
| PPMS | 182 (13.0) |
| Disease duration, mean (SD); median (IQR; range) | 8.5 (8.2); 6.0 (10.0; 0–50) |
| Disease duration categories, n (%) | |
| 0–5 years | 663 (47.2) |
| 6–10 years | 311 (22.1) |
| 11–15 years | 194 (13.8) |
| ≥16 years | 237 (16.9) |
| EDSS, mean (SD); median (IQR; range) | 3.5 (1.9); 3.0 (3.0; 1.0–9.0) |
| Previous and actual treatment, n (%) | |
| Treatment naïve | 665 (47.3) |
| Immunomodulation and selective immunosuppression | 532 (37.9) |
| IFN-β | 367 (26.1) |
| GA | 85 (6.0) |
| DMF | 22 (1.6) |
| FGL | 33 (2.4) |
| NTZ | 25 (1.8) |
| Immunosuppression | 208 (14.8) |
| Mx | 115 (8.2) |
| CTX | 52 (3.7) |
| CLA | 41 (2.9) |
RRMS—relapsing–remitting multiple sclerosis, SPMS—secondary progressive multiple sclerosis, PPMS—primary progressive multiple sclerosis, SD—standard deviation, IFN—interferon, GA—glatiramer acetate, DMF—dimethyl fumarate, FGL—fingolimod, NTZ—natalizumab, Mx—mitoxantrone, CTX—cyclophosphamide, and CLA—cladribine in vials for subcutaneous administration.